Zobrazeno 1 - 10
of 201
pro vyhledávání: '"James L Vacek"'
Autor:
Faith Rahman, John B. Hiebert, Janet D. Pierce, Bhanu Gupta, Qiuhua Shen, James L. Vacek, Kathryn J Krueger
Publikováno v:
Annals of Medicine and Surgery
Highlights • Manuscript Highlights. • HFpEF is associated with reduced ATP production in the myocardium. • Ubiquinol and d-ribose both contribute to the generation of myocardial ATP. • Both ubiquinol and d-ribose are being studied as suppleme
Autor:
Faith Rahman, Janet D. Pierce, John B. Hiebert, James L. Vacek, Qiuhua Shen, Kathryn J Krueger
Publikováno v:
Ann Transl Med
Objective In this review article, we briefly describe the status of treatment options for HFpEF and the role of mitochondrial dysfunction in the pathogenesis of HFpEF as an alternative therapeutic target. We also examine the mechanisms of D-ribose in
Autor:
Amanda R. Thimmesch, Diane E. Mahoney, Janet D. Pierce, Richard L. Clancy, John T. Pierce, James L. Vacek, John B. Hiebert, Andrew J. Sauer
Publikováno v:
Advances in Bioscience and Clinical Medicine, Vol 6, Iss 1, Pp 1-5 (2018)
Advances in bioscience and clinical medicine
Advances in bioscience and clinical medicine
Mitochondria are important organelles referred to as cellular powerhouses for their unique properties of cellular energy production. With many pathologic conditions and aging, mitochondrial function declines, and there is a reduction in the productio
Autor:
Andrea Natale, Madhav Lavu, Madhu Reddy, James L. Vacek, Donita Atkins, Dhanunjaya Lakkireddy, Jayasree Pillarisetti, Courtney Jeffrey, Mohit K. Turagam, Jodi Hurwitz, Katie Christensen, Muhammad R. Afzal, Luigi Di Biase, Raghuveer Dendi, Rhea Pimentel
Publikováno v:
International Journal of Cardiology. 236:221-225
Dofetilide is a class III antiarrhythmic drug that has been reported to be safe and efficacious in the treatment of atrial dysrhythmias with a known initial risk of QT prolongation and torsades de pointes (TdP). As a result, the Federal Drug Administ
Publikováno v:
Journal of cardiology. 74(5)
Heart failure with preserved ejection fraction (HFpEF) currently represents approximately 50% of heart failure (HF) cases in the USA and is increasingly recognized as a leading cause of morbidity and mortality. Recent data suggest that the prevalence
Autor:
Nicole L. Nollen, Tresza D. Hutcheson, Kimber P. Richter, Gary A. Salzman, Milind A. Phadnis, Sharon Fitzgerald, James L. Vacek, Edward F. Ellerbeck, Matthew R. Sharpe
Publikováno v:
JAMA Network Open
Key Points Question Compared with standard cessation approaches, can long-term nicotine replacement therapy lead to higher rates of cessation or reductions in carcinogen exposure among smokers with chronic obstructive pulmonary disease? Findings In t
Publikováno v:
Kansas Journal of Medicine
Autor:
Raffi K, Krikorian, James L, Vacek
Publikováno v:
Postgraduate medicine. 97(6)
Preview Methods of evaluating and managing peripheral arterial disease have undergone significant changes in the last several years. In this article, Drs Krikorian and Vacek examine the place that angioplasty and other percutaneous techniques have ta
Autor:
Larry R, Handlin, James L, Vacek
Publikováno v:
Postgraduate medicine. 95(4)
Preview There is little question that reperfusion therapy with thrombolytic agents benefits patients who meet the current eligibility requirements and receive therapy shortly after acute myocardial infarction. Less clear is whether this therapy would
Autor:
Jo Wick, Marilyn Werkowitch, Christy Russell, James L. Vacek, Ubolrat Piamjariyakul, Carol E. Smith
Publikováno v:
Heart & Lung. 44:466-473
Objectives (1) Test whether FamHFcare intervention could reduce patients' heart failure (HF)-related rehospitalizations and improve family caregiver outcomes; (2) calculate effect size on caregiver outcomes; and (3) evaluate the FamHFcare. Background